Acadia Gets Expedited FDA Review Path for Lead Drug

Acadia Pharmaceuticals Inc., a biotechnology company with $5 million in annual revenue, surged to its highest value in five years after saying it will gain a U.S. regulatory review of its lead drug sooner than anticipated.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.